MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - CIPLA
ASTRAZENECA PHARMA vs CIPLA - Comparison Results
ASTRAZENECA PHARMA 
Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
CIPLA
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Current Valuations
| ASTRAZENECA PHARMA | CIPLA | ASTRAZENECA PHARMA/ CIPLA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 86.8 | 29.6 | 293.0% | View Chart |
| P/BV | x | 19.1 | 3.1 | 609.3% | View Chart |
| Dividend Yield | % | 0.0 | 0.5 | - |
Financials
 ASTRAZENECA PHARMA  CIPLA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
CIPLA Mar-18 |
ASTRAZENECA PHARMA/ CIPLA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 663 | 192.8% | |
| Low | Rs | 883 | 479 | 184.3% | |
| Sales per share (Unadj.) | Rs | 228.4 | 189.0 | 120.8% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 17.6 | 58.9% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 34.0 | 47.8% | |
| Dividends per share (Unadj.) | Rs | 0 | 3.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.5 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 176.7 | 55.9% | |
| Shares outstanding (eoy) | m | 25.00 | 805.12 | 3.1% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 4.7 | 3.0 | 156.6% | |
| Avg P/E ratio | x | 104.2 | 32.5 | 321.2% | |
| P/CF ratio (eoy) | x | 66.4 | 16.8 | 395.9% | |
| Price / Book Value ratio | x | 10.9 | 3.2 | 338.5% | |
| Dividend payout | % | 0 | 17.1 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 459,724 | 5.9% | |
| No. of employees | `000 | 1.4 | 23.6 | 5.7% | |
| Total wages/salary | Rs m | 1,535 | 26,901 | 5.7% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 6,446.1 | 65.3% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 1,139.4 | 99.4% | |
| Avg. net profit/employee | Rs Th | 191.1 | 600.0 | 31.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 152,193 | 3.8% | |
| Other income | Rs m | 123 | 3,577 | 3.4% | |
| Total revenues | Rs m | 5,833 | 155,769 | 3.7% | |
| Gross profit | Rs m | 463 | 28,264 | 1.6% | |
| Depreciation | Rs m | 147 | 13,228 | 1.1% | |
| Interest | Rs m | 0 | 1,142 | 0.0% | |
| Profit before tax | Rs m | 438 | 17,470 | 2.5% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | -28 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | 0 | -775 | 0.0% | |
| Tax | Rs m | 179 | 2,501 | 7.2% | |
| Profit after tax | Rs m | 259 | 14,166 | 1.8% | |
| Gross profit margin | % | 8.1 | 18.6 | 43.7% | |
| Effective tax rate | % | 40.8 | 14.3 | 285.3% | |
| Net profit margin | % | 4.5 | 9.3 | 48.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 108,141 | 3.0% | |
| Current liabilities | Rs m | 2,070 | 38,322 | 5.4% | |
| Net working cap to sales | % | 20.0 | 45.9 | 43.5% | |
| Current ratio | x | 1.6 | 2.8 | 55.0% | |
| Inventory Days | Days | 72 | 97 | 74.6% | |
| Debtors Days | Days | 35 | 74 | 46.9% | |
| Net fixed assets | Rs m | 790 | 109,411 | 0.7% | |
| Share capital | Rs m | 50 | 1,610 | 3.1% | |
| "Free" reserves | Rs m | 2,419 | 140,682 | 1.7% | |
| Net worth | Rs m | 2,469 | 142,292 | 1.7% | |
| Long term debt | Rs m | 0 | 36,621 | 0.0% | |
| Total assets | Rs m | 4,605 | 228,606 | 2.0% | |
| Interest coverage | x | NM | 16.3 | - | |
| Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 0.7 | 186.2% | |
| Return on assets | % | 5.6 | 6.7 | 84.0% | |
| Return on equity | % | 10.5 | 10.0 | 105.4% | |
| Return on capital | % | 17.7 | 10.0 | 178.2% | |
| Exports to sales | % | 0 | 32.8 | 0.0% | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | 49,883 | 0.0% | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 300 | 51,691 | 0.6% | |
| Fx outflow | Rs m | 2,015 | 21,033 | 9.6% | |
| Net fx | Rs m | -1,715 | 30,658 | -5.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 14,628 | 0.6% | |
| From Investments | Rs m | -94 | -8,540 | 1.1% | |
| From Financial Activity | Rs m | NA | -3,855 | 0.0% | |
| Net Cashflow | Rs m | -6 | 2,431 | -0.2% | |
Share Holding
| Indian Promoters | % | 0.0 | 16.0 | - | |
| Foreign collaborators | % | 75.0 | 20.8 | 360.6% | |
| Indian inst/Mut Fund | % | 0.3 | 12.2 | 2.5% | |
| FIIs | % | 15.7 | 23.7 | 66.2% | |
| ADR/GDR | % | 0.0 | 1.1 | - | |
| Free float | % | 9.1 | 26.2 | 34.7% | |
| Shareholders | 12,856 | 161,166 | 8.0% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: AJANTA PHARMA GLENMARK PHARMA SUN PHARMA STRIDES PHARMA SCIENCE TTK HEALTHCARE
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)
Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)
May 24, 2019 | Updated on May 24, 2019For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)
Jun 3, 2019In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.
The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)
Jun 11, 2019One chart that predicted the NBFC crisis back in 2016.
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)
Jun 3, 2019The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?
Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)
Jun 6, 2019Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...
More|
| |
ASTRAZENECA PHARMA SHARE PRICE
Jun 14, 2019 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.